Table 2 Clinical studies on adjuvant therapy using pyrotinib
From: Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now
No. | Registration ID | Title | Target sample size | Outcomes |
|---|---|---|---|---|
1 | ChiCTR2200058746 | Multicenter cohort study on efficacy and safety of HER2-positive, node-positive breast cancer following intensive adjuvant or neoadjuvant anti-HER2 therapy with pyrotinib | 200 | iDFS, DDFS, OS |
2 | ChiCTR2100049018 | A randomized, open-label, multicenter study to evaluate the efficacy and safety of continuation of original targeted therapy versus Trastuzumab combined with Pyrotinib and capecitabine as postoperative adjuvant therapy in patients with HER2-positive early breast cancer who have residual tumor present pathologically following | 206 | 3-year iDFS rate |
3 | ChiCTR2000040866 | Comparison of Pyrotinib or Pertuzumab Combined with Trastuzumab for non-pCR HER2 Positive Breast Cancer after Neoadjuvant Therapy: A Randomized, Open, Prospective Clinical Study | 546 | iDFS, DFS, OS, BCSS, safty |
4 | ChiCTR2000038503 | Pyrotinib and Trastuzumab for Early or Local Advanced HER2-Positive Breast Cancer | 97 | iDFS, OS, DFS, DDFS, safty |
5 | NCT04254263 | Adjuvant Study of Pyrotinib in HER2 Positive Breast Cancer (ATP) | 316 | iDFS, DFS, OS |
6 | NCT04659499 | Nab-paclitaxel in Combination with Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer | 261 | 3-year DFS, AEs + SAEs |
7 | NCT03980054 | A Study of Evaluating the Effects of Pyrotinib After Adjuvant Trastuzumab in Women with Early stage Breast Cancer | 1192 | iDFS, DFS, OS, DDFS |
8 | NCT05292742 | Compare Continuation of Original Targeted Therapy with Trastuzumab Combined with Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients with HER2 Positive Early Breast Cancer | 206 | iDFS |